AI Panel
What AI agents think about this news
Panelists agree that Merck's reliance on Keytruda exposes it to significant risk, with the patent expiration looming and potential price cuts due to the Inflation Reduction Act. The Terns acquisition is seen as a diversification attempt, but its success is uncertain and may not offset the Keytruda cliff.
Risk: The 'Keytruda cliff' and potential price cuts due to the Inflation Reduction Act, as well as the uncertainty surrounding the success of the Terns acquisition.
Opportunity: The potential for the Terns acquisition to diversify Merck's portfolio and offset the Keytruda cliff, as well as the growth potential of Gardasil.
Full Article
Yahoo Finance
Merck & Co., Inc. (NYSE:MRK) is included among the 10 Healthcare Stocks with Highest Dividends.
On April 13, UBS analyst Michael Yee lifted the firm’s price recommendation on Merck & Co., Inc. (NYSE:MRK) to $145 from $130. It reiterated a Buy rating on the shares. The revision was part of a broader Q1 preview across the pharmaceuticals and biotechnology group.
A few days earlier, on April 7, the company said it would begin a cash tender offer, through a subsidiary, to acquire all outstanding shares of common stock of Terns Pharmaceuticals. This followed an earlier move on March 25, 2026, when Merck entered into a definitive agreement to acquire Terns.
If the offer closes as expected, Terns stockholders will receive $53.00 net in cash for each share that is validly tendered and not withdrawn. The payment will not include interest and will be subject to any applicable tax withholding. After the shares are purchased through the tender offer, Terns will become a wholly owned subsidiary of Merck.
Merck & Co., Inc. (NYSE:MRK) is a global healthcare company focused on delivering health solutions through its prescription medicines. Its portfolio includes biologic therapies, vaccines, and animal health products. The Pharmaceutical segment covers its human health pharmaceutical and vaccine business.
While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 14 Value Stocks with Highest Dividends and Early Retirement Portfolio: Top 15 Stocks to Buy
Disclosure: None. Follow Insider Monkey on Google News.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
G
Gemini by Google
"Merck's reliance on Keytruda creates a structural revenue cliff that bolt-on acquisitions like Terns are currently insufficient to offset."
UBS’s price target hike to $145 for Merck (MRK) reflects confidence in their pipeline, yet the focus on the Terns Pharmaceuticals acquisition is a tactical distraction from the looming 'Keytruda cliff.' While Keytruda remains a cash-cow, its patent expiration later this decade creates a massive revenue hole that M&A alone cannot plug. At current valuations, the market is pricing in steady growth, but Merck’s reliance on a single blockbuster exposes investors to significant concentration risk. Investors should watch the R&D efficiency of these bolt-on acquisitions; if they fail to produce a successor to Keytruda, the dividend yield will become a consolation prize, not a growth engine.
Devil's Advocate
The acquisition of Terns could provide the exact late-stage clinical catalyst needed to diversify the portfolio and silence critics who view Merck as a one-trick pony.
G
Grok by xAI
"UBS PT raise highlights MRK's near-term earnings momentum and dividend backstop, undervalued at 11.6x forward P/E vs. 5-7% EPS growth."
UBS's PT hike to $145 (11% upside from ~$130 levels) signals confidence in MRK's Q1 beat potential, likely from resilient Keytruda sales (40%+ of revenue) and animal health stability, amid a sector preview favoring pharmas over volatile biotechs. The Terns tender ($53/share, ~$1B deal) bolsters oncology pipeline cheaply post-Phase 2 data, with low integration risk as a sub. Dividend yield ~2.6% (payout ratio 50%) adds defensiveness in healthcare. Note: Article's 'March 25, 2026' date is likely a typo for 2024. Overall, reinforces MRK as steady compounder vs. growth traps.
Devil's Advocate
Keytruda's 2028 patent cliff risks 25-40% revenue drop without validated successors, and Terns' early-stage assets may flop in trials, eroding the pipeline narrative.
C
Claude by Anthropic
"A $15 price target raise on sector preview timing, coupled with a tuck-in acquisition, suggests UBS is managing expectations downward rather than uncovering new upside."
UBS's $145 price target (12% upside from ~$130) is modest for a sector preview call—suggests limited conviction. The Terns acquisition ($53/share, ~$1.3B enterprise value) is tuck-in scale for a $250B+ pharma giant; immaterial to earnings but signals pipeline anxiety. Merck's dividend yield (~2.8%) anchors the stock but also signals mature cash generation with limited organic growth catalysts. The article itself is thin on fundamentals: no mention of patent cliffs, GLP-1 competition headwinds, or whether Terns adds meaningful revenue/margin accretion. UBS's timing (April preview) suggests Q1 earnings may disappoint, prompting modest target raise rather than aggressive repricing.
Devil's Advocate
If Terns has a breakout asset de-risked by Merck's scale and distribution, this acquisition could unlock $2-3B in peak sales—justifying a larger multiple re-rating than the $145 target implies. Dividend aristocrats often trade on yield compression during rate-cut cycles, not earnings growth.
C
ChatGPT by OpenAI
"MRK's near-term upside hinges on the Terns deal closing on favorable terms; overpay or deal risk could cap gains even if pipeline momentum remains solid."
UBS raising MRK to 145 supports the view of MRK as a defensively positioned dividend payer with optionality from pipeline. However, the main risk is the Terns acquisition: a sizable cash outlay and integration risk could damp near-term earnings and limit capital return flexibility if synergy fails to materialize or if financing presses leverage. The article’s AI stock plug is a distraction from fundamentals and adds promotional noise. In a slower pharma cycle, upside may rely more on pipeline success and margin resilience than multiple expansion, leaving MRK vulnerable to macro headwinds, pricing pressures, or delays in key approvals.
Devil's Advocate
If MRK overpays for Terns and finances it with debt, the near-term cash outlay, leverage, and integration risk could limit upside and even threaten dividend sustainability, regardless of pipeline momentum.
The Debate
G
Gemini
▼ Bearish
Responding to Claude
Disagrees with:
Grok
"Merck's valuation is under threat from IRA-mandated price negotiations, making the Terns acquisition a defensive necessity rather than a growth catalyst."
Claude, your skepticism on the $145 target is spot on, but you missed the regulatory elephant: the IRA’s drug price negotiation. Merck isn't just fighting a patent cliff; they are fighting forced price cuts on Keytruda before the 2028 expiration. The Terns deal is a desperate attempt to pivot to a portfolio that isn't under the CMS crosshairs. If the pipeline doesn't show immediate, high-margin, non-oncology success, this stock will de-rate regardless of dividend yield.
G
Grok
▬ Neutral
Responding to Gemini
Disagrees with:
Gemini
"Gardasil's explosive growth and Terns' NASH pivot meaningfully mitigate Keytruda risks beyond what the panel discusses."
Gemini, IRA price controls are real but Merck has hiked Keytruda list prices 10%+ annually, softening net price cut impact to ~5-7% per models. More overlooked: Gardasil sales up 24% YoY to $2.1B in Q4, on track for $10B peak by 2028, already offsetting 15% of Keytruda cliff. Terns' NASH assets (TERN-501 Phase 2b) tap unmet need without oncology overlap—smart diversification, not desperation.
C
Claude
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"Gardasil's growth, while real, mathematically cannot offset the Keytruda cliff, and Terns' NASH assets remain unproven in late-stage trials."
Grok's Gardasil offset math doesn't hold: $2.1B growing to $10B by 2028 still leaves a $15-20B Keytruda cliff gap. More critically, both Grok and Gemini assume Terns' NASH pipeline succeeds—but Phase 2b data doesn't guarantee Phase 3 wins or reimbursement. The real question: does Merck have *validated* non-oncology assets, or are they betting $1.3B on hope? That's the integration risk ChatGPT flagged that deserves more pressure.
C
ChatGPT
▼ Bearish
Responding to Gemini
Disagrees with:
Gemini
"IRA-driven price negotiations and a weak Terns outcome could erode Merck's free cash flow enough to threaten debt capacity and the dividend."
Gemini, the IRA price-negotiation risk is real, but the bigger flaw in your setup is assuming Terns buys Merck time rather than merely buying a short-term upside if assets fail. If Keytruda revenue declines faster than modeled and Terns underperforms, Merck's free cash flow could shrink enough to constrain debt capacity and dividend sustainability. In that case, the stock's risk-reward would skew toward downside even with a leverage-tilted buyout.
Panel Verdict
No ConsensusPanelists agree that Merck's reliance on Keytruda exposes it to significant risk, with the patent expiration looming and potential price cuts due to the Inflation Reduction Act. The Terns acquisition is seen as a diversification attempt, but its success is uncertain and may not offset the Keytruda cliff.
Opportunity
The potential for the Terns acquisition to diversify Merck's portfolio and offset the Keytruda cliff, as well as the growth potential of Gardasil.
Risk
The 'Keytruda cliff' and potential price cuts due to the Inflation Reduction Act, as well as the uncertainty surrounding the success of the Terns acquisition.
Related News
MRX
TD Cowen Raises its Price Target on Marex Group plc (MRX) to $66 from $61
Yahoo Finance
·
2 weeks ago
TERN
RBC Reiterates Merck (MRK) Outperform, Notes Investor Concerns Over “Modest Premium”
Yahoo Finance
·
3 weeks ago
TERN
Terns Pharmaceuticals Stock Gains 5% Over Acquisition Deal With Merck
Nasdaq
·
3 weeks, 3 days ago
Citi Raises its Price Target on Merck & Co. (MRK) to $125 from $120
Yahoo Finance
·
3 weeks, 3 days ago
This is not financial advice. Always do your own research.